FDA Eyes Renewal for 'Safer' Cigarettes—Smokers, Weigh In!
Published Date: 5/13/2026
Notice
Summary
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Renewal Must Meet Section 911(g)(2) Tests
The applicant seeking renewal is pursuing an order under section 911(g)(2) of the FD&C Act and must demonstrate several statutory points, including that the order would promote public health, that claims are limited to reduced exposure or reduced levels of substances, that available scientific evidence reasonably predicts measurable and substantial reductions in morbidity or mortality, and that consumers will not be misled. These statutory demonstrations are required for the renewed modified-risk authorization.
Possible Continued Sale of 'Modified Risk' Cigarettes
The company 22nd Century Group Inc. has applied to renew FDA authorization to market VLN® King and VLN® Menthol King as modified risk tobacco products. These products previously received authorization on December 23, 2021; if the renewals are granted they would remain on the market with modified-risk claims (public comment for the applications opened May 13, 2026).
Public Comment Period and Document Posting Rules
FDA posted redacted application documents for public comment beginning May 13, 2026 and will set a closing date that is at least 120 days after this notice and at least 30 days after final documents are posted; the Agency will announce the final closing date at least 30 days in advance. Comments submitted electronically to regulations.gov will be posted publicly unless submitted as confidential written/paper submissions following FDA instructions.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13346 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medication Guides for Prescription Drug Products
The FDA is updating how it collects info about Medication Guides—those important leaflets that come with some prescription drugs to keep patients safe. This affects drug makers who must follow new rules about what info to include and how to share it. Comments on these changes are open until July 31, 2026, and the update aims to keep patients informed without adding extra costs.
2026-13140 — Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
2026-13139 — Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
Previous / Next Documents
Previous: 2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
Next: 2026-09545 — Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, M/V REMEDY
The government is asking for your thoughts on letting a foreign-built small passenger boat, the M/V REMEDY, operate in U.S. coastal waters carrying up to 12 passengers. This could affect U.S. boat builders and businesses that use American-made vessels, so they want to make sure it won’t hurt local jobs or trade. You have until June 12, 2026, to share your opinion—no cost changes yet, just a decision in the works!